These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 21527547)

  • 21. Immunization with A2 protein results in a mixed Th1/Th2 and a humoral response which protects mice against Leishmania donovani infections.
    Ghosh A; Zhang WW; Matlashewski G
    Vaccine; 2001 Oct; 20(1-2):59-66. PubMed ID: 11567746
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Studies on the protective efficacy of freeze thawed promastigote antigen of Leishmania donovani along with various adjuvants against visceral leishmaniasis infection in mice.
    Thakur A; Kaur H; Kaur S
    Immunobiology; 2015 Sep; 220(9):1031-8. PubMed ID: 26001730
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Evaluation of the immunogenicity and protective efficacy of killed Leishmania donovani antigen along with different adjuvants against experimental visceral leishmaniasis.
    Thakur A; Kaur H; Kaur S
    Med Microbiol Immunol; 2015 Aug; 204(4):539-50. PubMed ID: 25432859
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Enhanced protective efficacy of nonpathogenic recombinant leishmania tarentolae expressing cysteine proteinases combined with a sand fly salivary antigen.
    Zahedifard F; Gholami E; Taheri T; Taslimi Y; Doustdari F; Seyed N; Torkashvand F; Meneses C; Papadopoulou B; Kamhawi S; Valenzuela JG; Rafati S
    PLoS Negl Trop Dis; 2014 Mar; 8(3):e2751. PubMed ID: 24675711
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Studies on the protective efficacy and immunogenicity of Hsp70 and Hsp83 based vaccine formulations in Leishmania donovani infected BALB/c mice.
    Kaur J; Kaur T; Kaur S
    Acta Trop; 2011 Jul; 119(1):50-6. PubMed ID: 21530477
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Molecular, biochemical characterization and assessment of immunogenic potential of cofactor-independent phosphoglycerate mutase against Leishmania donovani: a step towards exploring novel vaccine candidate.
    Tandon R; Chandra S; Baharia RK; Misra P; Das S; Rawat K; Siddiqi MI; Sundar S; Dube A
    Parasitology; 2018 Apr; 145(4):508-526. PubMed ID: 28691653
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Immunization with a recombinant stage-regulated surface protein from Leishmania donovani induces protection against visceral leishmaniasis.
    Stäger S; Smith DF; Kaye PM
    J Immunol; 2000 Dec; 165(12):7064-71. PubMed ID: 11120835
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Identification of Leishmania infantum chagasi proteins in urine of patients with visceral leishmaniasis: a promising antigen discovery approach of vaccine candidates.
    Kashino SS; Abeijon C; Qin L; Kanunfre KA; Kubrusly FS; Silva FO; Costa DL; Campos D; Costa CH; Raw I; Campos-Neto A
    Parasite Immunol; 2012 Jul; 34(7):360-71. PubMed ID: 22443237
    [TBL] [Abstract][Full Text] [Related]  

  • 29. New Vaccine Formulations Containing a Modified Version of the Amastigote 2 Antigen and the Non-Virulent
    Almeida APMM; Machado LFM; Doro D; Nascimento FC; Damasceno L; Gazzinelli RT; Fernandes AP; Junqueira C
    Front Immunol; 2018; 9():465. PubMed ID: 29599776
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A Non-pathogenic Recombinant Leishmania Expressing Lipophosphoglycan 3 Against Experimental Infection with Leishmania infantum.
    Pirdel L; Farajnia S
    Scand J Immunol; 2017 Jul; 86(1):15-22. PubMed ID: 28426153
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Making an anti-amastigote vaccine for visceral leishmaniasis: rational, update and perspectives.
    Fernandes AP; Coelho EA; Machado-Coelho GL; Grimaldi G; Gazzinelli RT
    Curr Opin Microbiol; 2012 Aug; 15(4):476-85. PubMed ID: 22698479
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Kinesin motor domain of Leishmania donovani as a future vaccine candidate.
    Dey A; Sharma P; Redhu NS; Singh S
    Clin Vaccine Immunol; 2008 May; 15(5):836-42. PubMed ID: 18353921
    [TBL] [Abstract][Full Text] [Related]  

  • 33. gp63 in stable cationic liposomes confers sustained vaccine immunity to susceptible BALB/c mice infected with Leishmania donovani.
    Bhowmick S; Ravindran R; Ali N
    Infect Immun; 2008 Mar; 76(3):1003-15. PubMed ID: 18195029
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Antibody responses induced by Leish-Tec®, an A2-based vaccine for visceral leishmaniasis, in a heterogeneous canine population.
    Testasicca MC; dos Santos MS; Machado LM; Serufo AV; Doro D; Avelar D; Tibúrcio AM; Abrantes Cde F; Machado-Coelho GL; Grimaldi G; Gazzinelli RT; Fernandes AP
    Vet Parasitol; 2014 Aug; 204(3-4):169-76. PubMed ID: 24863572
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Vaccination with DNA encoding ORFF antigen confers protective immunity in mice infected with Leishmania donovani.
    Sukumaran B; Tewary P; Saxena S; Madhubala R
    Vaccine; 2003 Mar; 21(11-12):1292-9. PubMed ID: 12559811
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Studies on cocktails of 31-kDa, 36-kDa and 51-kDa antigens of Leishmania donovani along with saponin against murine visceral leishmaniasis.
    Kaur H; Thakur A; Kaur S
    Parasite Immunol; 2015 Apr; 37(4):192-203. PubMed ID: 25615543
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Immunization with the DNA-encoding N-terminal domain of proteophosphoglycan of Leishmania donovani generates Th1-type immunoprotective response against experimental visceral leishmaniasis.
    Samant M; Gupta R; Kumari S; Misra P; Khare P; Kushawaha PK; Sahasrabuddhe AA; Dube A
    J Immunol; 2009 Jul; 183(1):470-9. PubMed ID: 19542458
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Heterologous Immunization With Defined RNA and Subunit Vaccines Enhances T Cell Responses That Protect Against
    Duthie MS; Van Hoeven N; MacMillen Z; Picone A; Mohamath R; Erasmus J; Hsu FC; Stinchcomb DT; Reed SG
    Front Immunol; 2018; 9():2420. PubMed ID: 30386348
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Reduced pathogenicity of fructose-1,6-bisphosphatase deficient Leishmania donovani and its use as an attenuated strain to induce protective immunogenicity.
    Saini S; Ghosh AK; Das S; Singh R; Abhishek K; Verma S; Kumar A; Mandal A; Purkait B; Sinha KK; Das P
    Vaccine; 2018 Feb; 36(9):1190-1202. PubMed ID: 29395522
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Induction of protective cellular immune responses against experimental visceral leishmaniasis mediated by dendritic cells pulsed with the N-terminal domain of Leishmania infantum elongation factor-2 and CpG oligodeoxynucleotides.
    Agallou M; Pantazi E; Tsiftsaki E; Toubanaki DK; Gaitanaki C; Smirlis D; Karagouni E
    Mol Immunol; 2018 Nov; 103():7-20. PubMed ID: 30173073
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.